Group B streptococcus (GBS) is recognized as a leading cause of newborn infection [1]. The primary risk factor for neonatal GBS early-onset disease (EOD) is maternal colonization of the genitourinary and gastrointestinal tracts [1]. Approximately half of all women who carry GBS will transmit the bacteria to their newborns, typically during labor or after the rupture of membranes [1]. Without preventative measures, a small percentage of these exposed newborns will develop severe invasive infections [1].
Key Risk Factors for Newborns
While maternal colonization is the primary trigger, several other factors increase a newborn's vulnerability to early-onset GBS disease [1, 4]. Understanding these risks helps healthcare providers identify infants who require closer monitoring or immediate medical evaluation:
- Gestational age of less than 37 weeks [1, 4]
- Very low birth weight [1]
- Prolonged rupture of maternal membranes [1, 4]
- Intraamniotic infection [1, 4]
- Young maternal age and maternal black race [1]
- Immunologic immaturity typical of neonates [4]
Universal Prenatal Screening and Prevention
The implementation of key obstetric measures has successfully driven dramatic declines in perinatal sepsis caused by GBS [2, 4]. Standard prevention protocols rely heavily on universal prenatal screening [1]. Healthcare providers perform vaginal-rectal cultures for pregnant individuals, ensuring correct specimen collection and laboratory processing [1]. When GBS colonization is identified, the standard medical approach involves administering targeted intrapartum antibiotic prophylaxis—antibiotics given directly during labor [1, 4]. This timely intervention sharply reduces the rate of vertical transmission from mother to newborn [1, 4].
Balancing Antibiotic Use and Stewardship
While intrapartum antibiotics are vital for preventing early-onset GBS infections, modern clinical guidelines also emphasize responsible medication management. Professional medical organizations, including the Centers for Disease Control and Prevention and the American Academy of Pediatrics, continuously evaluate care strategies to optimize antibiotic use [3]. The goal is to provide robust infection protection for vulnerable infants while minimizing unnecessary exposure to empirical antibiotics for healthy, term newborns who are at low risk [3]. Coordinated communication between obstetric and pediatric care teams remains essential for achieving this balance [1].
Sources
- [1] Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion, Number 797. PubMed
- [2] Prevention of neonatal sepsis. PubMed
- [3] Antibiotic stewardship: reassessment of guidelines for management of neonatal sepsis. PubMed
- [4] Neonatal sepsis: progress towards improved outcomes. PubMed